These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32501499)

  • 1. An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts.
    Lane LC; Kuś A; Bednarczuk T; Bossowski A; Daroszewski J; Jurecka-Lubieniecka B; Cordell HJ; Pearce SHS; Cheetham T; Mitchell AL
    J Clin Endocrinol Metab; 2020 Sep; 105(9):e3277-84. PubMed ID: 32501499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric-onset and adult-onset Graves' disease share multiple genetic risk factors.
    Kuś A; Radziszewski M; Glina A; Szymański K; Jurecka-Lubieniecka B; Pawlak-Adamska E; Kula D; Wawrusiewicz-Kurylonek N; Kuś J; Miśkiewicz P; Płoski R; Bolanowski M; Daroszewski J; Jarząb B; Bossowski A; Bednarczuk T
    Clin Endocrinol (Oxf); 2019 Feb; 90(2):320-327. PubMed ID: 30358895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease.
    Kuś A; Szymański K; Peeters RP; Miśkiewicz P; Porcu E; Pistis G; Sanna S; Naitza S; Płoski R; Medici M; Bednarczuk T
    Clin Endocrinol (Oxf); 2015 Oct; 83(4):556-62. PubMed ID: 25345847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset.
    Skórka A; Bednarczuk T; Bar-Andziak E; Nauman J; Ploski R
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):679-82. PubMed ID: 15943829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts.
    Płoski R; Brand OJ; Jurecka-Lubieniecka B; Franaszczyk M; Kula D; Krajewski P; Karamat MA; Simmonds MJ; Franklyn JA; Gough SC; Jarząb B; Bednarczuk T
    PLoS One; 2010 Nov; 5(11):e15512. PubMed ID: 21124799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rs3827440, a nonsynonymous single nucleotide polymorphism within GPR174 gene in X chromosome, is associated with Graves' disease in Polish Caucasian population.
    Szymański K; Miśkiewicz P; Pirko K; Jurecka-Lubieniecka B; Kula D; Hasse-Lazar K; Krajewski P; Bednarczuk T; Płoski R
    Tissue Antigens; 2014 Jan; 83(1):41-4. PubMed ID: 24289805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study.
    Kurylowicz A; Ramos-Lopez E; Bednarczuk T; Badenhoop K
    Exp Clin Endocrinol Diabetes; 2006 Jun; 114(6):329-35. PubMed ID: 16868893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-2-adrenergic receptor gene polymorphism confers susceptibility to Graves disease.
    Jazdzewski K; Bednarczuk T; Stepnowska M; Liyanarachchi S; Suchecka-Rachon K; Limon J; Narkiewicz K
    Int J Mol Med; 2007 Jan; 19(1):181-6. PubMed ID: 17143563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility.
    Mitchell AL; Cordell HJ; Soemedi R; Owen K; Skinningsrud B; Wolff AB; Ericksen M; Undlien D; Husebye E; Pearce SH
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5139-45. PubMed ID: 19850680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA DQ2 HAPLOTYPE, EARLY ONSET OF GRAVES DISEASE, AND POSITIVE FAMILY HISTORY OF AUTOIMMUNE DISORDERS ARE RISK FACTORS FOR DEVELOPING CELIAC DISEASE IN PATIENTS WITH GRAVES DISEASE.
    Miskiewicz P; Gos-Zajac A; Kurylowicz A; Plazinska TM; Franaszczyk M; Bartoszewicz Z; Kondracka A; Pirko-Kotela K; Rupinski M; Jarosz D; Regula J; Ploski R; Bednarczuk T
    Endocr Pract; 2015 Sep; 21(9):993-1000. PubMed ID: 26121457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The -112G>A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves' disease in subsets of patients with elevated levels of immunoglobulin E.
    Chistiakov DA; Voronova NV; Turakulov RI; Savost'anov KV
    J Appl Genet; 2011 May; 52(2):201-7. PubMed ID: 21170691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis in young-age-of-onset Graves' disease reveals new susceptibility loci.
    Brown RS; Lombardi A; Hasham A; Greenberg DA; Gordon J; Concepcion E; Hammerstad SS; Lotay V; Zhang W; Tomer Y
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1387-91. PubMed ID: 24684463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations.
    Bednarczuk T; Hiromatsu Y; Fukutani T; Jazdzewski K; Miskiewicz P; Osikowska M; Nauman J
    Eur J Endocrinol; 2003 Jan; 148(1):13-8. PubMed ID: 12534352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population.
    Ichimura M; Kaku H; Fukutani T; Koga H; Mukai T; Miyake I; Yamada K; Koda Y; Hiromatsu Y
    Thyroid; 2008 Jun; 18(6):625-30. PubMed ID: 18578611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 4p14 and 6q27 variation with Graves disease: a case-control study and a meta-analysis of available evidence.
    Li FM; Liu L; Pang LN; Shen M; Lu HW; Zhang XH; Chu X; Song ZJ
    BMC Med Genet; 2017 May; 18(1):56. PubMed ID: 28521825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease.
    Kurylowicz A; Hiromatsu Y; Jurecka-Lubieniecka B; Kula D; Kowalska M; Ichimura M; Koga H; Kaku H; Bar-Andziak E; Nauman J; Jarzab B; Ploski R; Bednarczuk T
    Genes Immun; 2007 Oct; 8(7):532-8. PubMed ID: 17690684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HLA-DR, -DQ genotype and CTLA-4 gene polymorphism with Graves' disease in Japanese children.
    Iwama S; Ikezaki A; Kikuoka N; Kim HS; Matsuoka H; Yanagawa T; Sato H; Hoshi M; Sakamaki T; Sugihara S
    Horm Res; 2005; 63(2):55-60. PubMed ID: 15640608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both interleukin-23A polymorphism and serum interlukin-23 expression are associated with Graves' disease risk.
    Jia H; Tao F; Liu C; Guo T; Zhu W; Wang S; Cui B; Ning G
    Cell Immunol; 2015 Mar; 294(1):39-43. PubMed ID: 25670394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease.
    Zeitlin AA; Heward JM; Brand OJ; Newby PR; Franklyn JA; Gough SC; Simmonds MJ
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):380-4. PubMed ID: 16918960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.